Skip to content

Hidradentitis supprativa (HS) trial

Hidradenitis suppurativa is an inflammatory skin disease affecting apocrine bearing areas such as the axillae and groin, characterised by recurrent discharging abscesses and sinuses, inflammatory nodules and scarring. The Westmead Dermatology Department is currently recruiting patients with HS for a phase 2 study evaluating the efficacy of bimekizumab in patients with moderate to severe hidradenitis …

A successful education day in Onco-Dermatology

On the 2nd of December, we have successfully held our first “Skin effects of systemic anti-cancer therapies” education day at Westmead Hospital. Education is one of the missions of the CTSR (Centre for Translational Skin Research), and were sharing our knowledge regarding the diagnosis and management of skin effects of systemic oncology medications with dermatologists, …

Why moles disappear with anti-melanoma therapies?

Naevus lightening is a fascinating phenomenon found in patients on BRAF inhibitors and MEK inhibitors combination therapy (BiMiC) and checkpoint immunotherapy. We have recently published a study unravelling the mystery underlining this phenomenon. We biopsied 7 lightened naevi from metastatic melanoma patients on either BiMiC or checkpoint immunotherapy such as pembrolizumab. Under the microscope, we …

Non-melanoma skin cancer and SWATH Acquisition

Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra (SWATH) is one of the premier mass spectrometry acquisition strategies for identification and quantitation of proteins in a complex sample. Unlike other mass spectrometry strategies, SWATH technique allows comprehensive detection and quantitation of virtually every detectable analyte in a sample. Crossmatching these analytes with an …

Medical treatment for basal cell carcinoma

The main treatment of cancer is still surgery, but, for some cancers, medical treatment offers a important alternative. In Basal Cell Carcinoma (BCC), the use of imiquimod for superficial BCC is well stablished and approved in many countries. Recently, in Australia, another molecule, vismodegib, has been approved for the treatment of BCC. In this case, …

Dapsone and EGFR inhibitors

Our department feels privileged to have another oncodermatology publication in the Australasian Journal of Dermatology titled: “Epidermal growth factor receptor inhibitor‐induced papulopustular eruption successfully treated with low‐dose oral dapsone”. Patients on EGFR inhibitors frequently develop cutaneous adverse events including papulopustular eruptions (also known as acneiform eruptions), hair loss and xerosis. This is a paper about …